Aptose Biosciences Inc. Files Amendment to Registration Statement

TL;DR

<b>Aptose Biosciences Inc. has filed an S-1/A amendment, detailing its corporate information and registration under the Securities Act of 1933.</b>

AI Summary

Aptose Biosciences Inc. (APTOF) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. Aptose Biosciences Inc. filed an S-1/A amendment on January 22, 2024. The filing is a registration statement under the Securities Act of 1933. The company's principal executive offices are located at 251 Consumers Road, Suite 1105, Toronto, Ontario, Canada M2J 4R3. Aptose Biosciences U.S. Inc. is listed as the agent for service at Unit 120, 12770 High Bluff Drive, San Diego, California 92130. The filing includes information on the company's former names, including LORUS THERAPEUTICS INC. and IMUTEC PHARMA INC.

Why It Matters

For investors and stakeholders tracking Aptose Biosciences Inc., this filing contains several important signals. This amendment provides updated corporate and legal information for Aptose Biosciences Inc., crucial for investors to understand the company's structure and regulatory compliance. The filing details the company's principal executive offices and agent for service in the US, which are important for legal and communication purposes related to its securities.

Risk Assessment

Risk Level: low — Aptose Biosciences Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating ongoing regulatory processes rather than immediate financial performance or operational changes.

Analyst Insight

Monitor future filings for details on the proposed offering and the company's strategic direction.

Key Numbers

• S-1/A — Form Type (Amendment to Registration Statement)
• 333-275870 — Registration Number (SEC File Number)
• 2024-01-22 — Filing Date (Date of filing with SEC)
• 2014-09-05 — Date of Name Change (From Aptose Biosciences Inc. to LORUS THERAPEUTICS INC.)

Key Players & Entities

• Aptose Biosciences Inc. (company) — Registrant
• 2024-01-22 (date) — Filing Date
• Securities Act of 1933 (regulatory) — Act under which registration is filed
• 251 Consumers Road, Suite 1105 Toronto, Ontario, Canada M2J 4R3 (address) — Registrant's principal executive offices
• Aptose Biosciences U.S. Inc. (company) — Agent for service
• Unit 120, 12770 High Bluff Drive San Diego, California 92130 (address) — Agent for service address
• LORUS THERAPEUTICS INC. (company) — Former company name
• IMUTEC PHARMA INC (company) — Former company name

Forward-Looking Statements

• Aptose Biosciences Inc. will initiate a new equity offering within the next 12 months. (Aptose Biosciences Inc.) — medium confidence, target: January 2025

FAQ

Industry Context

Aptose Biosciences Inc. operates in the biotechnology sector, focusing on the development of novel therapies.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track future SEC filings from Aptose Biosciences Inc. for updates on their business and financial performance.
3. Research the company's therapeutic pipeline and clinical trial progress.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates or corrections to the initial registration statement.

Key Financial Figures

• $2.38 — rice of the common shares on Nasdaq was $2.38 per common share and on January 10, 202
• $3.14 — on January 10, 2024, the TSX reported C$3.14 per common share. The assumed combined
• $2 — fered Share and accompanying Warrant is $2.38, which is the last reported sale pri
• $0.01 — e Offered Share at an exercise price of $0.01 per Offered Share. Each Pre-Funded Warr
• $2.50 — arrants at an assumed offering price of $2.50 per combined Private Placement Share an
• $4.0 m — gregate gross proceeds of approximately $4.0 million, without giving effect to any fee
• $4 million — fy its obligation to fund the remaining $4 million owed to us pursuant the Subscription Ag
• $2.37 — nation, at an assumed offering price of $2.37 per additional common share and $0.01 p

Filing Documents

• d613667ds1a.htm (S-1/A) — 1561KB
• d613667dex51.htm (EX-5.1) — 19KB
• d613667dex52.htm (EX-5.2) — 8KB
• d613667dex231.htm (EX-23.1) — 4KB
• d613667dexfilingfees.htm (EX-FILING FEES) — 33KB
• g613667dsp26.jpg (GRAPHIC) — 3KB
• g613667dsp27.jpg (GRAPHIC) — 2KB
• g613667dsp62.jpg (GRAPHIC) — 10KB
• g613667g0104013617344.jpg (GRAPHIC) — 18KB
• g613667g0104021039339.jpg (GRAPHIC) — 4KB
• g613667g1202020638135.jpg (GRAPHIC) — 4KB
• 0001193125-24-011444.txt (&nbsp;) — 1682KB

USE OF PROCEEDS

USE OF PROCEEDS 35

UNDERWRITING

UNDERWRITING 38 CONCURRENT PRIVATE PLACEMENT OFFERING 42

BUSINESS

BUSINESS 43 CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS 56 DESCRIPTION OF OUR COMMON SHARES 68 DESCRIPTION OF OUR SECURITIES WE ARE OFFERING 69 DIRECTORS & MANAGEMENT 73

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 77 DIRECTOR COMPENSATION 83

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 85 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 96 LEGAL MATTERS 96 EXPERTS 96 WHERE YOU CAN FIND MORE INFORMATION 96

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the SEC). You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions Where You Can Find More Information in this prospectus. Neither we nor the underwriter have authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about, and to observe, any restrictions as to the offering and the distribution of this prospectus applicable to those jurisdictions. We further note that the representations, warranties and covenants made in any agreement that is filed as an exhibit to any document that is incorporated by reference in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in s

financial statements, or cause us to fail to meet our reporting obligations or fail to prevent fraud;

financial statements, or cause us to fail to meet our reporting obligations or fail to prevent fraud; our broad discretion in how we use the proceeds of the sale of Offered Shares, Pre-Funded Warrants and Warrants; our ability to expand our business through the acquisition of companies or businesses; and other risks detailed from time-to-time in our on-going filings with the SEC and Canadian securities regulators, and those which are discussed under the heading Risk Factors in this prospectus. Should one or more of these risks or uncertainties materialize, or should the assumptions described in the sections entitled Risk Factors in this prospectus underlying those forward-looking statements prove incorrect, actual results may vary materially from those described in the forward-looking More detailed information about these and other factors is included in this prospectus under the section entitled Risk Factors. Although we have attempted to identify factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Forward-looking statements are based upon our beliefs, estimates and opinions at the time they are made and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or circumstances should change, except as required by applicable law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Forward-looking Except as required under applicable securities legislation, we undertake no obligation to publicly update or r

View Full Filing

View this S-1/A filing on SEC EDGAR